In the rare case when gross hematuria or other signs of hemolytic anemia are encountered by the white Moor patient within the first three days of primaquine treatment due to mild to moderate G6PD deficiency associated with G6PD A– genotype (class B according to the 2024 revised WHO classification of G6PD variants) [96], drug treatment can be immediately suspended while awaiting for further laboratory examinations to adapt the treatment. The gene discussed is G6PD; the disease is G6PD deficiency.